Drugs that affect blood coagulation, fibrinolysis and hemostasis

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

This chapter reviewed 2019 publications that identify side effects of drugs that affect blood coagulation, fibrinolysis and hemostasis. Publications on warfarin, apixaban, dabigatran, rivaroxaban, edoxaban, betrixaban, bivalirudin, argatroban, unfractionated heparin, low molecular weight heparin, fondaparinux, aminocaproic acid, tranexamic acid, idarucizumab, andexanet alfa, and tissue plasminogen activators have been reviewed. In addition to the well-known risks of these medications such as bleeding or thrombotic events, rare adverse events reports were recognized.

Original languageEnglish (US)
Title of host publicationA Worldwide Yearly Survey of New Data in Adverse Drug Reactions
EditorsSidhartha D. Ray
PublisherElsevier B.V.
Pages337-360
Number of pages24
ISBN (Print)9780128203309
DOIs
StatePublished - Jan 2020

Publication series

NameSide Effects of Drugs Annual
Volume42
ISSN (Print)0378-6080

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug guides
  • Pharmacology (medical)

Keywords

  • Adverse events
  • Adverse reactions
  • Aminocaproic acid
  • Andexanet alfa
  • Apixaban
  • Argatroban
  • Betrixaban
  • Bivalirudin
  • Dabigatran
  • Direct acting anticoagulants
  • Edoxaban
  • Fondaparinux
  • Idarucizumab
  • Low molecular weight heparin
  • Rivaroxaban
  • Side effects
  • Tissue plasminogen activators
  • Tranexamic acid
  • Unfractionated heparin
  • Warfarin

Fingerprint

Dive into the research topics of 'Drugs that affect blood coagulation, fibrinolysis and hemostasis'. Together they form a unique fingerprint.

Cite this